Selective blockade of Kv1.3 channels hinders chronic inflammatory processes via an immune-sparing mechanism
Description
Chronic inflammatory and autoimmune diseases place a heavy burden on society and all current medications are based on general immunosuppression. Chronically activated T-cells play a key role in the pathomechanism of these conditions. Unlike acutely activated T cells, these persistently activated cells exhibit a unique dependency on Kv1.3 potassium channels. Therefore, selective inhibition of Kv1.3 is a promising tool to treat chronic inflammatory and autoimmune diseases safely and effectively without general immunosuppression.
Our lead compound has demonstrated a robust in vivo effect in a rat dermatitis model.
IL-6
Next-generation precision medicine against IL-6 trans-signaling for chronic inflammation
New treatment for chronic inflammatory and autoimmune diseases through selective inhibition of proinflammatory pathways
Indication
Chronic inflammatory and autoimmune diseases
Mechanism of action
Selective "Trans" IL-6 signaling specific therapy to target exclusively the pathogenetic proinflammatory pathway while sparing physiological immune functions
Description
Chronic inflammation is the key pathological process behind autoimmune diseases. Present therapies are based on non-specific immunosuppression and thereby associated with numerous side effects. Safe and effective treatment is possible via highly selective partial blockade of pathogenic IL-6 signaling. All current drugs on the market are monoclonal antibodies (mAbs) blocking IL-6 signaling globally leading to side effects like upper respiratory tract infections, neutropenia or acute pancreatitis. Our project employs an immune sparing mechanism of action by selectively targeting IL-6 trans-signaling while leaving the classical signaling and its physiological role untouched minimizng side effects and maximizing the efficiency.
Our platform specialized for miniprotein-based precision therapies aiming to provide a next-generation treatment with supreme specificity and extreme affinity.
CNS/IL-6
Shuttled IL-6 trans-signaling inhibitor for neuroinflammatory diseases
IL-6 trans-signaling inhibitor shuttled into the CNS
Indication
Neuroinflammatory diseases
Mechanism of action
Selective "Trans" IL-6 signaling specific therapy shuttled into the CNS, targeting exclusively the pathogenetic proinflammatory pathway while sparing physiological immune functions
Description
Further details coming soon.
CNS/New Target #1
Shuttled and/or BBB penetrant miniprotein for neuroinflammatory diseases
Undisclosed target
Indication
Neuroinflammatory diseases
Mechanism of action
Undisclosed
Description
Further details coming soon.
CNS/New Target #2
Shuttled and/or BBB penetrant miniprotein for neuroinflammatory diseases
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
